Comparison
GHRP-2 vs. Sermorelin
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Growth
CAS no.
158861-67-7
86168-78-7
Molecular weight
817.93 g/mol
3358 g/mol
Half-life
0.5 h
0.2 h
Sequence
D-Ala-D-2-Naphthyl-Ala-Ala-Trp-D-Phe-Lys-NH2YADAIFTNSYRKVLGQLSARKLLQDIMSRMechanism of action
GHRP-2
GHRP-2 binds with high affinity to the GH secretagogue receptor (GHSR-1a) in the pituitary and hypothalamus. Activation leads to rapid release of pulsatile growth hormone. Unlike GHRH, GHRP-2 acts via a separate pathway and can be combined synergistically with GHRH to elicit maximal GH responses in provocation tests.
Sermorelin
Synthetic analogue of the first 29 amino acids of human growth-hormone-releasing hormone (GHRH). Stimulates pulsatile endogenous growth-hormone secretion from the pituitary via the GHRH receptor. Very short plasma half-life — pharmacodynamic effect lasts several hours nevertheless.
Evidence base
Highest evidence
Human trial
Human RCT
Studies
4
5
of which in humans
4
3
Effects recorded
3
3
Open conflicts
0
1
Documented adverse events
1
3